A Team Of Specialists

Karl R. Olsen, M.D. Curriculum Vitae - Go Back

Education:

1972-1976 Stanford University, Stanford, California, B.S. in Chemistry

1976-1980 Northwestern University Medical School, Chicago, Illinois

 

Post Doctoral Training:

1985-1986 Instructor - Chief Resident, University of Miami, Bascom Palmer Eye Institute, Miami, Florida

1984-1985 Retina Vitreous Fellowship, Duke University Eye Center, Durham, North Carolina

1981-1984 Residency Training, University of Miami, Bascom Palmer Eye Institute, Miami, Florida

1980-1981 Internship Training, Evanston Hospital, Northwestern University, Evanston, Illinois

 

Appointment and Positions:

Academic:

1986-1990 Assistant Professor of Ophthalmology, University of Miami, Miami, Florida

1990 Clinical Assistant Professor of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA

 

Membership in Professional and Scientific Societies

1975-present Phi Beta Kappa

1980-present American Medical Association

1982-present The Association for Research in Vision and Ophthalmology

1984-present Bascom Palmer Eye Institute Alumni Association

1985-1990 Dade County Medical Association

1985-present Fellow, The American Academy of Ophthalmology

1985-1990 Florida Medical Society

1986-1987 National Institutes of Health Collaborative Ocular Melanoma Study, Executive Committee

1987-1992 National Institutes of Health Collaborative Ocular Melanoma Study, Radiation Physics Committee

1987-present Pan American Society of Ophthalmology

1990-present Pennsylvania Medical Society

1990-present Allegheny County Medical Society

1990-present Atlantic Coast Fluorescein Club

1991-present The Retina Society

 

EXTRA-DEPARTMENTAL ADMINISTRATIVE AND COMMITTEE RESPONSIBILITIES

1988 Dade County Medical Association - Continuing Medical Education Committee

1987-1990 University of Miami Cancer Committee

1989-1990 Collaborative Ocular Melanoma Study - Executive Committee

1989-1990 University of Miami - Animal Rights Committee

1991-2004 Collaborative Ocular Melanoma Study - Radiation Oncology and Physics Committee

1999-2003 Pittsburgh Ophthalmology Society Treasurer

2000-2008 Allegheny County Medical Society: Child Health Committee

2003-2005 Pittsburgh Ophthalmology Society President-elect

2005-2007 Pittsburgh Ophthalmology Society President

2007-2008 Pittsburgh Ophthalmological Society Nominating Committee

2007-present Pennsylvania Academy of Ophthalmology Board Member

2007-present Allegheny County Medical Society Delegate to the Pennsylvania Medical Society

2010-present American Academy of Ophthalmology (AAO) Member Council

2010-present Pennsylvania Academy of Ophthalmology Treasurer

2011-present Allegheny County Medical Society Board Member

2011-present Allegheny County Medical Society Membership Committee

Certification and Licensure

1985 Board Certified in Ophthalmology

Medical Licensure:

1983 State of Florida Medical

1984 State of North Carolina

1990 State of Pennsylvania

Honors:

1972 American Legion Post 42 - Excellence in Citizenship Award

1975 Phi Beta Kappa - Awarded as a Junior

1976 Merck Sharp and Dohme- Award for excellence in Chemistry

1981 Evanston Hospital - Flexible Intern of the Year

Pittsburgh Magazine Featured in Best Doctors in Pittsburgh

2006-2007 Murray F. McCaslin, MD Outstanding Clinical Preceptors of the Year Award Presented by the Senior Residents of the Department of Ophthalmology University of Pittsburgh School of Medicine 2006-2007

2008 State Affairs Star Award - Pennsylvania Academy of Ophthalmology, Current Concepts in Ophthalmology

2010 Best Doctors in America “ Selected 1996 every year to 2009-2010 database

2010 Guide to America's Top Ophthalmologists 2010 Edition Consumer's Research Council of America

2011 Distinguished Service Award from American Academy of Ophthalmology

2011 Pennsylvania Academy of Ophthalmology (PAO) Humanitarian Award

2011 Top Ophthalmologist in Pittsburgh, PA 2011 International Association of Healthcare Professionals spotlighted in The Leading Physicians of the World

 

Publications:

SCIENTIFIC ARTICLES IN REFEREED JOURNALS

Alfonso E, Friedland B, Hupp S, Olsen K, Senikowich K, Sklar V and Forster R. Neisseria Gonorrhea Conjunctivitis; An Outbreak During an Epidemic of Acute Hemorrhagic Conjunctivitis. J Am Med Assoc 1983;250(6):794-795

Landers M, Robinson D, Olsen K, and Rinkoff J. Slit Lamp Fluid Gas Exchange and Other Office Procedures Following Vitreoretinal Surgery. Arch Ophthalmol 1985;103:967-972

Johnson RN, Olsen K, Hernandez E. Tissue plasminogen activator treatment of postoperative intraocular fibrin. Ophthalmology 1988;95:592-596

Olsen K, Blumenkranz M, Hernandez E, Hajek A, and Hartzer M. Fluorouracil Therapy of Intraocular Greene Melanoma in the Rabbit. Arch Ophthalmol 1988;106(6):812-815

O'Grady G, Parel J, Lee W, Flynn H, Olsen K, Blankenship G, and Clarkson J. Hypodermic Stainless Steel Tacks and Companion Inserter Designed for Peripheral Fixation of the Retina. Arch Ophthalmol 1988;106:270-275

Russell S and Olsen K. Predictors of Scleral Rupture and the Role of Vitrectomy in Severe Blunt Ocular Trauma. Am J Ophthalmol 1988;105:253-257

Johnson R, Olsen K, and Hernandez E. Intravitreal Plasminogen Activator: Treatment of Experimental Vitreous Hemorrhage. Arch Ophthalmol 1989;107:891-894

Lambrou F, Chilbert M, Mieler W, Williams G, and Olsen K. A New Technique for Subchoroidal Implantation of Experimental Malignant Melanoma. Invest Ophthalmol Vis Sci 1988;29:995-998

Olsen K, Parel J, Fliesler S, Lee W, and Hernandez E. Biodegradable Mechanical Retinal Fixation. Arch Ophthalmol 1989;107:735-741

Brod R, Olsen K, Packer A, and Ball S. The Site of Operating Microscope Light-Induced Injury on the Human Retina. Am J Ophthalmol 1989;107:390-397

Houdek P, Schwade J, Medina A, Poole C, Olsen K, Nicholson D, Byrne S, Quencer R, Hinks R, and Pisciotta V. MR Technique for Localization and Verification Procedures in Intraocular Brachytherapy. Int J Radiation Oncology Biol Phys 1989;17:1111-1114

Heilskov T, Joondeph B, Olsen K, and Blankenship G. Late Endophthalmitis After Trans-Scleral Fixation of a Posterior Chamber Intraocular Lens. Arch Ophthalmol 1989;107:1427

Albert D, Olsen K, Parel J, Hernandez E, Lee W, and Quencer R. Magnetic Resonance Imaging and Retinal Tacks. Arch Ophthalmol 1990;108:302-321

Wade E, Flynn H, Olsen K, Blumendranz M, and Nicholson D. Subretinal Hemorrhage Management by Pars Plana Vitrectomy and Internal Drainage. Arch Ophthalmol 1990;108(7):973-978

Winward K, Dabbs C, Olsen K, and Hernandez E. Photodynamic Therapy of Choroidal Greene Melanoma in the Rabbit. Arch Ophthalmol 1990;108:588-594

Hay A, Olsen K, and Nicholson D. Bleeding Complications in Thrombocytopenic Patients Undergoing Ophthalmic Surgery. Am J Ophthalmol 1990;109:482-483

Johnson M, Olsen K, Hernandez E, Irvine W, and Johnson R. Retinal Toxicity of Recombinant Tissue Plasminogen Activator. Arch Ophthalmol 1990;108:259-263

Sneed S, Byrne S, Mieler W, Nicholson D, Olsen K, and Hughes J. Choroidal Detachment Associated with Malignant Choroidal Tumors. Ophthalmology 1991;98(6):963-970

Curless R, Flynn J, Olsen K, and Post M. Leber Congenital Amaurosis in Siblings with Diffuse Dysmyelination. Ped Neurol 1991;7(3):223-225

Johnson M, Olsen K, and Hernandez E. Tissue Plasminogen Activator Treatment of Experimental Subretinal Hemorrhage. Retina II 1991:250-258

Irvine W, Johnson M, Hernandez E, and Olsen K. Retinal Toxicity of Human Tissue Plasminogen Activator in Vitrectomized Rabbit Eyes. Arch Ophthalmol 1991;109(5):718-722

Smiddy W, Flynn J, Nicholson D, Clarkson J, Gass J, and Olsen K. Results and Complications in Treated Retinal Breaks. Am J Ophthal 1991;112:623-631

Ksander B, Rubsamen P, Olsen K, Cousins S, and Streilein J. Studies of Tumor-Infiltrating Lymphocytes from a Human Choroidal Melanoma. Invest Ophthalmol Vis Sci 1991;32(13):3198-3208

Nichols C, Boldt H, Mieler W, Han D, and Olsen K. Ocular Injuries Caused by Elastic Cords. Arch Ophthalmol 1991;109(3):371-372

Johnson M, Olsen K, and Hernandez E. Tissue Plasminogen Activator Thrombolysis during Surgical Evacuation of Experimental Subretinal Hemorrhage. Ophthalmology 1992;99:515-521

Yang C, Olsen K, Schwade J, Houdek P, Markoe A, Pisciotta V, and Wu X. Dose rate effect of 125I Irradiation on Normal Rabbit Eyes and Experimental Choroidal Melanoma. Exp Eye Research 1993;57:577-585

Cohn R and Olsen K. Retinal Commotio and Tears from a Water Balloon Injury. Arch Ophthalmol 1994;112(8):1021

Johnson R, McDonald H, Lewis H, Grand M, Murray T, Mieler W, Johnson M, Boldt H, Olsen K, Tornambe P, and Folk J. Traumatic Macular Hole, Observations, Pathogenesis and Results of Vitrectomy Surgery. Ophthalmology 2001;108:853-857

Olsen K. Age-related macular degeneration: Pearls for Primary Care. Current Concepts in Ophthalmology. Vol. 11 April 2007

Luiz H. Lima, Ketan Laud, Pinchas Rosenberg, Roy Tuller, Karl Olsen and Lawrence A. Yannuzzi Ophthalmomyiasis with a Singular Subretinal Track. Am J Ophthal 2010;150:731-736

 

SILICONE STUDY PUBLICATIONS

The Silicone Study Group. Classification of Proliferative Vitreoretinopathy Used in the Silicone Study. Ophthalmology 1989;96(6):765-771

The Silicone Study Group. The Validity and Reliability of Photographic Documentation of Proliferative Vitreoretinopathy. Ophthalmology 1989;96(3):352-357

The Silicone Study Group. The Effect of Therapeutic Treatment Crossovers on the Power of Clinical Trials: Controlled Clinical Trials. Arch Ophthalmol 1990;11(5):314-326

The Silicone Study Group. Methods, Statistical Features, and Baseline Results of a Standardized, Multi-Centered Ophthalmologic Surgical Trial: Controlled Clinical Trials. Arch Ophthalmol 1991;12(3):438-455

The Silicone Study Group. Vitrectomy with Silicone Oil or Sulfur Hexafluoride Gas in Eyes with Severe Proliferative Vitreoretinopathy: Results of a Randomized Clinical Trial Silicone Study Report 1. Arch Ophthalmol 1992;110:770-779

The Silicone Study Group. Vitrectomy with Silicone Oil or Perfluoropropane Gas in Eyes with Severe Proliferative Vitreoretinopathy: Results of a randomized Clinical Trial: Silicon Study Report 2. Arch Ophthalmol 1992;110:780-792

McCuen B, Azen S, Stern W, et al. Vitrectomy with Silicone Oil Perfluoropropane Gas in Eyes with Severe Proliferative Vitreoretinopathy: Results in Group 1 Versus Group 2: Silicone Study Report 3. Retina 1993;13(4):279-84

Barr C, Lai M, Lean J, et al. Post-operative Intraocular Pressure Abnormalities in the Silicone Study: Silicone Study Report 4. Ophthalmology 1993; Nov;100(11):1629-35

Blumenkranz M, Azen S, Aaberg T, et al. Relaxing Retinotomy with Silicone Oil or Long-Acting Gas in Eye with Severe Proliferative Vitreoretinopathy: Silicone Study Report 5. Am J Ophthalmol 1993 Nov 15;116(5):557-64

 

COMS (Collaborative Ocular Melanoma Study) PUBLICATIONS

Straastsma B, Fine S, Earle J, Hawkins B, Diener-West M, McLaughlin J, and The Collaborative Ocular Melanoma Study Group. Enucleation Versus Plaque Irradiation for Choroidal Melanoma. Ophthalmology 1988;95:1000-1004

Marcus, D, Minkovitz J, Wardwell S, Albert D, and The Collaborative Ocular Melanoma Study Group. The Value of Nucleolar Organizer Regions in Uveal Melanoma. Am J Ophthalmol 1990;110:527-534

Collaborative Ocular Melanoma Study Group. Accuracy of Diagnosis of Choroidal Melanomas in the Collaborative Ocular Melanoma Study. COMS Report No. 1. Arch Ophthalmol 1990;108:1268-1273

Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition: The Collaborative Ocular Melanoma Study. COMS Report No. 3. Controlled Clin Trials 1993;14:362-391

Wells C, Bradford RH, Fish GE, Straatsma BR, Hawkins BS for the COMS Group: Choroidal melanoma in American Indians. Arch Ophthalmol 1996;114:1017-1018

Collaborative Ocular Melanoma Study Group. Mortality in Patients With Small Choroidal Melanoma. COMS Report No. 4 Arch Ophthalmol 1997;115:886-893

Collaborative Ocular Melanoma Study Group: Factors predictive of growth and treatment of small choroidal melanoma. COMS Report No. 5 Arch Ophthalmol 1997;115:1537-1544

Collaborative Ocular Melanoma Study Group: Histopathologic characteristics of uveal melanomas in eye enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6 Am J Ophthalmol 1998;125:745-766

Collaborative Ocular Melanoma Study Group: Sociodemographic and Clinical Predictors of Participation in Two Randomized Trials: Findings from the Collaborative Ocular Melanoma Study. COMS Report No. 7. Controlled Clin Trials 2001;22:526-537

Grossniklaus HE, Albert DM, Green WR, Conway BP, Hovland KR for the Collaborative Ocular Melanoma Study Group: Clear cell differentiation in choroidal melanoma. COMS Report No. 8 Arch Ophthalmol 1997;115:894-898

Collaborative Ocular Melanoma Study: The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. I. Characteristics of patients enrolled and not enrolled. COMS Report No. 9. Am J Ophthalmol 1998;125:767-778

Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. II. Initial mortality findings. COMS Report No. 10. Am J Ophthalmol 1998;125:779-796, 1998;126:622 [Correction]

Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. III. Local complications and observations following enucleation. COMS Report No. 11. Am J Ophthalmol 1998;126:362-372

Collaborative Ocular Melanoma Study Group: Echography (Ultrasound) Procedures for the Collaborative Ocular Melanoma Study. COMS Report No. 12. J Ophth Nurs technol Part I 1999;18(4):143-149, Part II 1999;18(5):219-232

Collaborative Ocular Melanoma Study Group: Consistency of observations from echograms made centrally in the Collaborative Ocular Melanoma Study. COMS Report No. 13. Ophthalmic Epidemoil 2002;Feb;9(1):11-27

Collaborative Ocular Melanoma Study Group: Cause-specific mortality coding:Â Methods in the Collaborative Ocular Melanoma Study. COMS Report No. 14. Control Clin Trials 2001,22:248-262

Collaborative Ocular Melanoma Study Group: Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study COMS Report No. 15 Arch Ophthalmolo 2001:119:670-676

Collaborative Ocular Melanoma Study Group: Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS Report No. 16. Ophthalmology 2001:108(2):348-366

Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. II. Characteristics of patients enrolled and not enrolled. COMS Report No. 17. Arch Ophthalmol 2001:119:951-965

Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. III. Initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001:119:969-982

Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. Local treatment failure and enucleation in the first 5 years after brachytherapy.ÂCOMS Report No. 19. Ophthalmology 2002:198:2197-2206

Collaborative Ocular Melanoma Study Group: Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997. Findings from patients evaluated at Collaborative Ocular Melanoma Study centers. COMS Report No. 20. Arch Ophthalmol 2003:121:1156-1162

Collaborative Ocular Melanoma Study Group: Comparison of clinical, echographic, and histologic measurements from eyes with medium-sized choroidal melanoma in the Collaborative Ocular Melanoma Study. COMS report No. 21. Arch Ophthalmol 2003:121:1163-1171

Collaborative Ocular Melanoma Study Group: Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS report No. 22. Ophthalmology 2004:May;111(5):966-76

Collaborative Ocular Melanoma Study Group: Screening for metastasis from choroidal melanoma: Report No. 23. J Clin Oncol. 2004:Jun 15;22(12):2438-44

Collaborative Ocular Melanoma Study (COMS) Randomized Trial of Pre-enucleation Radiation of Large Choroidal Melanoma: IV. Ten-year Mortality Findings and Prognostic Factors. COMS report No. 24. Am J Ophthalmology 2004;138:936-951

Mobley RY, Moy CS, Reynolds SM, Diener-West M, Newhouse MM, Kerman JS and Hawkins BS for the Collaborative Ocular Melanoma Study Group. Time trends in personnel certification and turnover in the Collaborative Ocular Melanoma Study. Clinical Trials 2004:1:377-386

Collaborative Ocular Melanoma Study (COMS) Second Primary Cancers After Enrollment in the COMS Trials for Treatment of choroidal melanoma. COMS report No. 25. Arch Ophthalmol 2005:123:601-604

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma v. Twelve-Year Mortality Rates and Prognostic Factors: COMS report No. 28. Arch Ophthalmol 2006:124:1684-1693

Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27. Ophthalmology. 2007 Jul;114(7):1263-71. Epub 2007 Mar 6.

 

QUALITY OF LIFE: COMS (COLLABORATIVE OCULAR MELANOMA STUDY) PUBLICATIONS

COMS Quality of Life Study Group: Quality of life assessment in the Collaborative Ocular Melanoma Study: Design and methods. COMS-QOL Report no. 1. Ophthalmic Epidemiol 1999;6(1):5-17

COMS Quality of Life Group: Incorporating a quality of life assessment into an ongoing multicenter clinical trial. COMS-QOLS Report No. 2. Arch Ophthalmology 2003 July;121(7):1010-1020

Melia BM, Moy CS, McCaffrey L: Quality of Life in patients with choroidal melanoma: A pilot study. Ophthalmic Epidemiol 1999:6:19-28

 

DIABETES CONTROL AND COMPLICATION TRIAL

The Diabetes Control and Complications Trial Research Group. Assessment of hemoglobin A1c in the Diabetes Control and Complications Trial (DCCT). Clin chem 1987;33:2267-71

The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New Engl J Med 1993;329:977-986

The Diabetes Control and Complications Trial Research Group. Baseline analysis of renal function in the Diabetes Control and Complications Trial. Kidney International 1993;43:668-674

The Diabetes Control and Complications Trial Research Group. The Effect ofIntensive Diabetes Treatment on the Progression of Diabetic Retinopathy in Insulin-Dependent Diabetes Mellitus: The Diabetes Control and Complications Trial. Arch Ophthalmol 1995;113:36-51

The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes and Complications Trial. Diabetes 1995;44:968-983

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int. 1995;June 47(6):1703-20

Progression of retinopathy with intensive versus conventional treatment in the Control and Complications Trial. Diabetes Control and Complications Trial Group. Ophthalmology 1995;April 102(4):647-661

Retinopathy and Nephropathy in patients with type 1 diabetes four years after intensive therapy. The Diabetes Control and Complications Trial/Epidemiology Diabetes Interventions and Complications Research Group. N Engl J Med 2000; Feb 10;342(6):381-9


ENDOPHTHALMITIS VITRECTOMY STUDY

The Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study: A Randomized Trial of Immediate Vitrectomy and of Intravenous Antibiotics for the Treatment of Postoperative Bacterial Endophthalmitis. Archives of Ophthalmology December 1995; 113:1479‘1496.

Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, Kelsey SF, and the Endophthalmitis Vitrectomy Study Group: The Endophthalmitis Vitrectomy Study: Spectrum and Susceptibilities of Microbiologic Isolates. American Journal of Ophthalmology July 1996; 122:117.

Doft BH, Barza M: Optimal Management of Postoperative Endophthalmitis and Results of the Endophthalmitis Vitrectomy Study. Current Opinion in Ophthalmology 1996; 7;III:894.

The Endophthalmitis Vitrectomy Study Group. Microbiologic Factors and Visual Outcome in the Endophthalmitis Vitrectomy Study. American Journal of Ophthalmology, December 1996;122:830846.

Wisniewski SR, Hammer ME, Grizzard WS, Kelsey SF, Everett D, Packo KH, Yarian DL, Doft BH, for the Endophthalmitis Vitrectomy Study Group: The Investigation of Hospital Charges Related to the Treatment of Endophthalmitis in the Endophthalmitis Vitrectomy Study. Ophthalmology May 1977; 104:739745.

Bannerman TL, Rhoden DL, McAllister SK, Miller JM, Wilson LA, and the Endophthalmitis Vitrectomy Study Group. The Source of Coagulase Negative Staphylococci in the Endophthalmitis Vitrectomy Study. Archives of Ophthalmology 1997; 115:357‘361.

Johnson MW, Doft BH, Kelsey SF, Barza M, Wilson LA, Barr CC, Wisniewski SR, and the Endophthalmitis Vitrectomy Study Group. The Endophthalmitis Vitrectomy Study: Relationship Between Clinical Presentation and Microbiologic Spectrum. Ophthalmology 1997; 104:261272.

Barza M, Pavan PR, Doft BH, Wisniewski SR, Wilson LA, Han DP, Kelsey SF, and the EVS Study Group. Evaluation of Microbiological Diagnostic Techniques in Postoperative Endophthalmitis in the EVS. Archives of Ophthalmology 1997;115:1142‘1150.

Doft, B.H. The Endophthalmitis Vitrectomy Study. In: Kertes PJ, Conway MD: Clinical Trials in Ophthalmology: A Summary and Practice Guide. Williams & Wilkins, Media PA, 1998;97‘111.

Doft BH, Kelsey SK, Wisniewski SR. Additional Procedures after the Initial Vitrectomy or Tap/Biopsy in the Endophthalmitis Vitrectomy Study (EVS). Ophthalmology 1998;105:707‘716.

Johnson MW, Doft BH, Kelsey SF, Barza M, Wilson LA, Barr CC, Wisniewski SR, and the Endophthalmitis Vitrectomy Study Group. The Endophthalmitis Vitrectomy Study: Relationship Between Clinical Presentation and Microbiologic Spectrum. Abstract; Ophthalmology Digest 1998:8‘11.

Han DP, Wisniewski SR, Kelsey SF, Doft BH, Barza M, Pavan PR, and the Endophthalmitis Vitrectomy Study Group. Microbiological Yields and Complication Rates of Vitreous Needle Aspiration Versus Mechanized Vitreous Biopsy in the Endophthalmitis Vitrectomy Study. Retina 1999;19:98‘102.

Wisniewski, SR, Kelsey, SK, Groer‑Fitzgerald S, Doft, BH, and the Endophthalmitis Vitrectomy Study Group. Characteristics After Cataract Extraction or Secondary Lens Implantation Among Patients Screened for the Endophthalmitis Vitrectomy Study. Ophthalmology 2000;107:1274-1282

Doft BH, Kelsey SF, Wisniewski SR., and the Endophthalmitis Vitrectomy Study Group. Retinal Detachment in the Endophthalmitis Vitrectomy Study. Archives of Ophthalmology 2000;118:1661-1665

Doft BH, Kelsey, SF, Wisniewski, SR, Groer-Fitzgerald S. and the Endophthalmitis Vitrectomy Study Group: Diabetes and Postoperative Endophthalmitis in the Endophthalmitis Vitrectomy Study. Archives of Ophthalmology 2001;119:650-656.

SUPPLEMENTAL THERAPEUTIC OXYGEN FOR PRETHRESHOLD RETINOPATHY OF PREMATURITY (STOP ROP)

Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000 Feb;105(2):295-310

On "Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes".J AAPOS 2000 April;4(2):65-66

 

EARLY TREATMENT FOR RETINOPATHY OF PREMATURITY

Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised Indications for the Treatment of Retinopathy of Prematurity. Results of the Early Treatment for Retinopathy of Prematurity Randomized Trial. Arch Ophthalmol 2003;121:1684-1696

Prevalence and Course of Strabismus in the First Year of Life for Infants With Prethreshold Retinopathy of Prematurity. Arch Ophthalmol 2006;124:766-773

 

THERAPY OF AGE-RELATED MACULAR DEGENERATION WITH PHOTODYNAMIC THERAPY

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 1999;117:1329-1345

Verteporfin In Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: one-year results of a randomized clinical trial - VIP Report 1. Ophthalmology 2001;108:841-852

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) study Group. Photodynamic therapy of subfoveal choroidal vascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001; Feb 119:(2):198-207

Verteporfin In Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: two-year results of a randomized clinical trial - VIP Report 2. American Journal of Ophthalmology 2001;131:541-560

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Photodynamic Therapy of subfoveal choroidal neovascularization with Verteporfin:Â Fluorescein angiographic guidelines for evaluation and treatment TAP and VIP Report No. 2 Arch Ophthalmol 2003; 121:1253-1268 (Sept. 2003)

Kaiser PK, Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension. TAP Report No. 8. Graefes Arch Clin Exp Ophthalmol. 2006 Mar 15

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7. Arch Ophthalmol. 2005;123:1283-1285 (Sept. 2005)

Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-ear results of a randomized clinical trial. Arch Ophthalmol. 2005;123:448-457 (April 2005)

VIP Report No. 5 Writing Committee. Verteporfin in photodynamic therapy: Report No. 5. [letter]. Ophthalmology. 2004;111:2144 (Nov. 2004)

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group, and Verteporfin in Photodynamic Therapy (VIP) Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials - TAP and VIP Report No. 3. Am J Ophthalmol. 2004; 137:683-696 (Apr. 2004)

Bressler SB, Pieramici DJ, Koester JM, Bressler NM for the TAP Study Group. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management - TAP Report No. 6. Arch Ophthalmol. 2004;124:325-329 (Mar. 2004)

Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: TAP and VIP Study Report No.4. Retina 2004;24:1-12 (Feb. 2004).

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No. 1. Am J Ophthalmol, 2003;136;407-418 (Sept. 2003)

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP Report No. 3. Arch Ophthalmol. 2002;120:1443-1454 (Nov. 2002)

Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 5. Arch Ophthalmol. 2002;120:1307-1314 (Oct. 2002)

Rubin GS, Bressler NM, Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation - TAP Report No. 4. Retina. 2002;22:536-544 (Oct. 2002)

Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2 [letter]. Am J Ophthalmol. 2002;133:168-169 (Jan. 2002)

 

(AMDRT) Age-Related Macular Degeneration Radiotherapy Trial

Marcus DM, Peskin E, Maguire M, Weissgold D, Alexander J, Fine S, Followill D, AMDRT Research Group. The Age-Related Macular Degeneration Radiotherapy Trial (AMDRT): One Year Results from a Pilot Study. Am J Ophthalmol 2004:Nov;138(5):818-828

 

(SCORE) Standard Care vs Corticosteroid for Retinal Vein Occlusion Study

The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study System for Evaluation of Optical Coherence Tomograms SCORE Study Report 4. Arch Ophthalmol. 2009;127(11):1461-1467

BOOKS AND CHAPTERS

Olsen K, Gass J and Janet L. Davis. Diffuse Unilateral Subacute Neuroretinitis Syndrome. Chapter 97, in Retina: (Fourth Edition) Section 6, 1721-1730, In: Ryan SJ, ed: Retina, CV Mosby Company; St. Louis, (4th edition published 2004)

Olsen K and Curtin V. Enucleation and Plaque Treatment. in Principles and Practice of Ophthalmology: Clinical Practice Albert D and Jakobiec F, eds. W.B. Saunders, Philadelphia

Murray T, Johnson R and Olsen K. Enucleation and Plaque Treatment. in Principles and Practice of Ophthalmology: Clinical Practice Albert D and Jakobiec F, eds. W.B. Saunders, Philadelphia (2nd Edition)

 

PUBLISHED ABSTRACTS

Olsen K, Blumenkranz M, and Luty G. Pathologic Responses of the Iris Vasculature. Invest Ophthalmol Vis Sci 1987;28:291 Suppl

Mieler W, Chilbert M, Williams G, Burke J, Lambrou F, Olsen K, Pellin J, and Green D. Endoexcimer Ablative Photodecomposition of Choroidal Melanoma in a Rabbit Model. Invest Ophthalmol Vis Sci 1987;28:211Â Suppl

Johnson R, Olsen K, and Tseng S. Human Tissue Plasminogen Activator Treatment of Post-operative Intraocular Fibrin. Invest Ophthalmol Vis Sci 1987;28:211Â Suppl

Olsen K, Parel J, Hernandez E, Lee W, Davis J, Blankenship G, and O'Grady G. Biodegradable Mechanical Retinal Fixation. Invest Ophthalmol Vis Sci 1987;28:291 Suppl

Dabbs C, Olsen K, and Hernandez E. Photochemical Ablation of Experimentally Induced Choroidal Melanoma. Invest Ophthalmol Vis Sci 1988;29:393 Suppl

Johnson R, Olsen K, and Hernandez E. Intravitreal Tissue Plasminogen Activator: Treatment of Experimental Vitreous Hemorrhage. Invest Ophthalmol Vis Sci 1988;29:405 Suppl

Brod R, Olsen K, Packer A, and Ball S. The Site of Operating Microscope Focal Illumination on the Retina of the Human Eye. Invest Ophthalmol Vis Sci 1988;29:413 Suppl

Olsen K. Ocular Melanoma Study and Its Clinical Significance. Section One of the Southern Regional Update Course. The American Academy of Ophthalmology in Cooperation with Bascom Palmer Eye Institute

Johnson M, Olsen K, Johnson R, and Hernandez E. Toxicity of Intravitreal Tissue Plasminogen Activator in the Rabbit. Invest Ophthalmol Vis Sci 1990;31:197Â Suppl

Yang C, Olsen K, and Cousins S. Detection of Cellular Proliferation within the Vitreous during Experimental PVR by Flow Cytometry. Invest Ophthalmol Vis Sci 1990;31:197 Suppl

Johnson M, Olsen K, and Hernandez E. Tissue Plasminogen Activator Treatment of Experimental Subretinal Hemorrhage. Invest Ophthalmol Vis Sci 1990;31:307 Suppl

Irvine W, Olsen K, Johnson M, and Hernandez E. Retinal Toxicity of Human Tissue Plasminogen Activator. Invest Ophthalmol Vis Sci 1990;31:307 Suppl

Johnson M, Olsen K, and Hernandez E. Tissue Plasminogen Activator in the Surgical Evacuation of Subretinal Blood. Invest Ophthalmol Vis Sci 1991;32:685 Suppl

Cousins S, Yang C, O'Grady G, Rubsamen P, and Olsen K. Flow Cytometric Analysis of Vitreous Infiltrates from Human Eyes with Retinal Detachment. Invest Ophthalmol Vis Sci 1991;32:768 Suppl

Yang C, Olsen K, and Cousins S. Quantification of Vitreous Proliferation Stimulating Activity in Eyes with Experimental Proliferative Vitreoretinopathy. Invest Ophthalmol Vis Sci 1991;32:768 Suppl

Ksander B, Rubsamen P, Olsen K, Cousins S. and Streilein J. Human Choroidal Melanomas are Infiltrated with Antigen-Specific and Non-Specific Lypmphocytes. Invest Ophthalmol Vis Sci 1991;32:938 Suppl